The potential benefits of unrelated donor marrow transplantation are offset by the immunologic
complications of graft-versus-host disease (GVHD) and infection. Therefore, we used …

Acute GVHD remains a major cause of morbidity and mortality after allogeneic hematopoietic
stem cell transplantation (HSCT). In a retrospective analysis, the response of 443 HSCT …

The success of allogeneic hematopoietic cell transplantation (HCT) is typically assessed as
individual complications, including graft-versus-host disease (GVHD), relapse, or death, yet …

We studied the safety and clinical outcomes of patients treated with umbilical cord blood (UCB)-derived
regulatory T cells (Tregs) that expanded in cultures stimulated with K562 cells …

Umbilical cord blood (UCB) transplantation is potentially curative for acute leukemia. This
analysis was performed to identify risk factors associated with leukemia relapse following …

To develop a novel acute graft-versus-host disease (GVHD) risk score, we examined the GVHD
clinical stage and grade of 1723 patients at the onset of treatment with systemic steroids. …

Acute graft-versus-host disease (GVHD) occurs less frequently after umbilical cord blood
transplantation (UCBT). More recent investigations include the use of 2 partially human …

Autologous hematopoietic stem cell transplantation (ASCT) has become standard therapy
for primary refractory (PR REF) or relapsed (REL) Hodgkin’s lymphoma (HL); however, more …

The breast cancer susceptibility gene BRCA2 has recently been identified as identical to the
Fanconi anemia (FA) gene FANCD1. Here we expand the clinical implications of this …

Grades 2-4 acute graft-versus-host disease (GVHD) occurs in approximately 35% of matched,
related donor (MRD) allogeneic hematopoietic cell transplantation (HCT) recipients. We …